GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against high-consequence infectious diseases and solid tumor cancers, announced on September 10, 2026, that it has requested a hearing before the Nasdaq Hearings Panel to appeal a delisting determination received on August 27, 2026. The determination relates to the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The hearing is scheduled for October 13, 2026, and the request has stayed any suspension or delisting action pending the hearing and any extension period granted by the Panel. Consequently, GeoVax’s common stock is expected to continue trading on The Nasdaq Capital Market under the symbol “GOVX” at least through that period.
The company’s ability to maintain its Nasdaq listing is significant for investors and stakeholders, as it affects liquidity, access to capital, and overall market confidence. At the hearing, GeoVax intends to present its plan to regain and maintain compliance with Nasdaq listing standards. David Dodd, Chairman and CEO, commented, “We remain committed to maintaining GeoVax’s Nasdaq listing and look forward to presenting our compliance plan to the Hearings Panel. Importantly, the Nasdaq process does not change our strategic priorities or our focus on execution.”
Dodd emphasized that the company continues to advance GEO-MVA toward its planned pivotal Phase 3 clinical program, pursue opportunities to strengthen manufacturing and global preparedness capabilities, and engage potential strategic, funding, and development partners. He added, “Our focus remains on building long-term value from GeoVax’s vaccine and immuno-oncology programs while addressing the Company’s near-term corporate and financing priorities.”
GeoVax’s priority program is GEO-MVA, an investigational Modified Vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026 to address the need for expanded orthopoxvirus vaccine supply and biodefense preparedness. In parallel, GeoVax is pursuing manufacturing and product innovations to support broader access and preparedness, while evaluating strategic partnerships and funding opportunities.
In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings. The company also maintains a broader MVA-based vaccine platform and intellectual property portfolio addressing high-consequence infectious diseases and global health preparedness.
The Nasdaq listing appeal and the reaffirmation of strategic priorities come at a critical time for GeoVax. Maintaining its listing is essential for raising the capital required to fund its clinical programs, and the outcome of the hearing could impact investor perception and the company’s ability to execute its long-term strategy. For more information, visit www.geovax.com.
